Literature DB >> 15177770

Axonal damage in multiple sclerosis: a complex issue in a complex disease.

Nikolaos Grigoriadis1, Tamir Ben-Hur, Dimitrios Karussis, Ioannis Milonas.   

Abstract

Multiple sclerosis is no longer considered to simply be an autoimmune demyelinating disease. Axonal destruction is another central pathological feature and a contributor to the accumulating disability of disease progression. The mechanism underlying axonal pathology has not been fully clarified but does not appear to be a simple one. The relationship between axonal damage and other components of the pathological features such as demyelination, inflammation and remyelination are under intense investigation. Experimental data suggest that therapeutic interventions such as the induction of rapid remyelination may lead to the protection of axons. In addition to immunomodulation, future strategies for neuroprotection may be of great importance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177770     DOI: 10.1016/j.clineuro.2004.02.017

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  10 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 3.  Oligodendrocyte fate after spinal cord injury.

Authors:  Akshata Almad; F Rezan Sahinkaya; Dana M McTigue
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

4.  Enolase and arrestin are novel nonmyelin autoantigens in multiple sclerosis.

Authors:  Farzin Forooghian; Roy K Cheung; W Clay Smith; Paul O'Connor; Hans-Michael Dosch
Journal:  J Clin Immunol       Date:  2007-04-10       Impact factor: 8.317

5.  MS14, an Iranian herbal-marine compound for the treatment of multiple sclerosis.

Authors:  Amrollah Ahmadi; Gholameza Habibi; Mehdi Farrokhnia
Journal:  Chin J Integr Med       Date:  2010-08-08       Impact factor: 1.978

6.  Enolase autoantibodies and retinal function in multiple sclerosis patients.

Authors:  Farzin Forooghian; Grazyna Adamus; Melanie Sproule; Carol Westall; Paul O'Connor
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.535

7.  Stem cells for spinal cord regeneration: Current status.

Authors:  Zain A Sobani; Syed A Quadri; S Ather Enam
Journal:  Surg Neurol Int       Date:  2010-12-25

8.  Virus-mediated autoimmunity in Multiple Sclerosis.

Authors:  Nikolaos Grigoriadis; Georgios M Hadjigeorgiou
Journal:  J Autoimmune Dis       Date:  2006-02-19

Review 9.  Does inflammation in an autoimmune disease differ from inflammation in neurodegenerative diseases? Possible implications for therapy.

Authors:  Michal Schwartz; Oleg Butovsky; Jonathan Kipnis
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

10.  Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.

Authors:  Jan Traub; Sarah Traffehn; Jasmin Ochs; Silke Häusser-Kinzel; Schirin Stephan; Robert Scannevin; Wolfgang Brück; Imke Metz; Martin S Weber
Journal:  Brain Pathol       Date:  2019-03-05       Impact factor: 6.508

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.